ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
New first-line treatment for recurrent or metastatic squamous cell carcinoma of head and neck: does one size fit all?
Therapeutic Radiology and Oncology
◽
10.21037/tro.2020.03.02
◽
2020
◽
Vol 4
◽
pp. 5-5
Author(s):
Naomi Kiyota
◽
Yoshinori Imamura
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Related Documents
Cited By
References
Observational study of the cetuximab relative dose intensity (RDI) in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Data on the maintenance and every two weeks use (DIRECT study)
Annals of Oncology
◽
10.1093/annonc/mdw376.19
◽
2016
◽
Vol 27
◽
pp. vi334
◽
Cited By ~ 2
Author(s):
J. Guigay
◽
E. Chamorey
◽
P. Céruse
◽
F. Mornex
◽
M. Degardin
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Observational Study
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Dose Intensity
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
123MO Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial
Annals of Oncology
◽
10.1016/j.annonc.2021.10.142
◽
2021
◽
Vol 32
◽
pp. S1432
Author(s):
D.A. Colevas
◽
K. Misiukiewicz
◽
A.T. Pearson
◽
J. Fayette
◽
J.R. Bauman
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Trial
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13355993.791652823
◽
2012
◽
Author(s):
Marco Merlano
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13355993.14726100
◽
2011
◽
Author(s):
Jan Vermorken
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03)
Annals of Oncology
◽
10.1093/annonc/mdz449.043
◽
2019
◽
Vol 30
◽
pp. xi32
Author(s):
J. Fayette
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Standard Chemotherapy
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Modified docetaxel, cisplatin and fluorouracil therapy as a first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study.
Journal of Clinical Oncology
◽
10.1200/jco.2016.34.15_suppl.e17503
◽
2016
◽
Vol 34
(15_suppl)
◽
pp. e17503-e17503
Author(s):
Nebi Serkan Demirci
◽
Sercan Aksoy
◽
Nuriye Özdemir
◽
Taner Babacan
◽
Gokmen Umut Erdem
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Head And Neck Cancer
◽
Retrospective Study
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck
Cancer
◽
10.1002/cncr.30256
◽
2016
◽
Vol 122
(24)
◽
pp. 3803-3811
◽
Cited By ~ 19
Author(s):
Antonio Jimeno
◽
Jean-Pascal Machiels
◽
Lori Wirth
◽
Pol Specenier
◽
Tanguy Y. Seiwert
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Phase Ib
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Cetuximab + platinum-based therapy (PBT) as a first-line treatment for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): An observational study (ENCORE)
Annals of Oncology
◽
10.1093/annonc/mdy287.013
◽
2018
◽
Vol 29
◽
pp. viii377
Author(s):
C. Le Tourneau
◽
M. Ghiani
◽
M.C. Cau
◽
R. Depenni
◽
G. Ronzino
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Observational Study
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study
Current Medical Research and Opinion
◽
10.1080/03007995.2016.1257984
◽
2016
◽
Vol 33
(3)
◽
pp. 401-407
◽
Cited By ~ 5
Author(s):
Nebi Serkan Demirci
◽
Sercan Aksoy
◽
Nuriye Yıldırım Özdemir
◽
Gökmen Umut Erdem
◽
Melike Ozcelik
◽
...
Keyword(s):
Squamous Cell Carcinoma
◽
Head And Neck Cancer
◽
Retrospective Study
◽
Cell Carcinoma
◽
Head And Neck
◽
Squamous Cell
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Faculty Opinions recommendation of Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.13355993.14726135
◽
2011
◽
Author(s):
Pol Specenier
Keyword(s):
Squamous Cell Carcinoma
◽
Cell Carcinoma
◽
Head And Neck
◽
Phase Ii
◽
Squamous Cell
◽
Phase Ii Study
◽
Line Treatment
◽
First Line
◽
Metastatic Squamous Cell Carcinoma
◽
First Line Treatment
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close